Efficacy and Safety of mRNA SARS-CoV2 Vaccination in Heart Transplant Recipients

Abstract

PurposeData on immunologic response to SARS-CoV2 vaccination in heart transplant recipients are scarce. We investigated the efficacy and safety of mRNA SARS-CoV2 vaccination in this patient population.MethodsIn a retrospective single-center study we included 54 consecutive adult heart transplant recipients who received 2 doses of mRNA SARS-CoV2 vaccine between January 1 and June 30, 2021. All patients were followed for 112±28 days after the second dose. At the end of follow-up we measured humoral response to SARS-CoV2 by assessing total antibody levels to the receptor-binding domain of SARS-CoV2 spike (S) protein using anti-RBD immunoassay. Anti-S antibody serum levels ≥250 BAU/mL were considered protective. At the same time, cellular response was measured by the IFN-γ response to S-peptide stimulation of recipient T lymphocyte populations. Protective cellular response was defined as more than 0,3% of IFN-γ responsive T cells.ResultsOf 54 recipients, 44 (81%) were male with a mean age of 63±8 years and a mean time from transplantation of 6.6±4.0 years. Immunosupressive regimen consisted of tacrolimus (mean C0 level 7.4±1.7 μg/mL), mycophenolate mofetil (mean dose 2120±419 mg) and steroids (mean dose 2.5±0.9 mg). The majority of patients received BTN162b2 vaccine (83%), and 17% of recipients were vaccinated with mRNA-1273. During follow-up, a humoral response was present in 24 (44%) of the recipients (median anti-S serum level 35.5 BAU/mL). We found no difference in humoral response between patients receiving BNT162b2 and mRNA-1273 vaccine (median anti-S serum level 68.3 BAU/mL vs. 15.5 BAU/mL, P=0.81). Protective humoral response was observed in 6 (11%) of the recipients (median anti-S serum level 557 BAU/mL). A cellular response to vaccine was present in 3 (6%) of the recipients; all 3 displayed a protective level of reponse. No recipients developed simultaneous protective humoral and cellular responses. Recipient age was the only predictor of protective humoral response (55±11 years in responders vs. 65±8 years in nonresponders; P=0.01). In 3 (6%) recipients we found worsening of allograft function requiring hospital admission, which occured within 1 month after receiving the second dose of vaccine.ConclusionIn heart transplant recipients, mRNA SARS-CoV2 vaccination appears to be of limited efficacy and may, in some cases, be associated with worsening of allograft function.